A Randomized, Open-label Phase II Trial of the Anti-HCV Activity and Safety of VGX-410 (Mifepristone) at 3 Dose Levels in HCV Infected Patients.

Trial Profile

A Randomized, Open-label Phase II Trial of the Anti-HCV Activity and Safety of VGX-410 (Mifepristone) at 3 Dose Levels in HCV Infected Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2009

At a glance

  • Drugs Mifepristone (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors VGX Pharmaceuticals
  • Most Recent Events

    • 18 Dec 2007 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 02 Sep 2007 Status change from recruiting to in progress.
    • 20 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top